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Abstract 
Introduction: Neonates with hypoxic-ischemic encephalopathy (HIE) undergoing 
hypothermia may benefit from adjunctive therapy with melatonin. However, melatonin 
safety, pharmacokinetics (PK), and dosage in this sensitive population is still unknown.  
Methods and results: This study assessed the PK and safety of melatonin enteral 
administration to neonates with HIE undergoing hypothermia.  Melatonin was infused at 0.5 
mg/kg in five neonates with HIE undergoing hypothermia. Infusion started 1 h after the 
neonates reached the target temperature of 33.5 °C. Blood samples were collected before and 
at selective times after melatonin infusion. Abdominal complications or clinically significant 
changes in patients’ vital signs were not found during or after melatonin. The peak plasma 
concentration reached 0.25 µg/ml. The area under the curve in 24 h was 4.35 µg/mL*h.  
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Discussion: Melatonin half-life and clearance were prolonged, and the distribution volume 
decreased compared to adults. In silico simulation estimated that the steady state can be 
reached after four infusions. Hypothermia does not affect melatonin PK. In humans high 
blood concentrations with lower doses can be achieved compared to animal experimentation, 
although intravenous administration is advised in the neonate population. Our study is a 
preparatory step for future clinical studies aimed at assessing melatonin efficacy in HIE.  
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| INTRODUCTION 
Hypoxic-ischemic encephalopathy (HIE) is the major cause of neurological morbidity 
in the term infant. Currently, therapeutic hypothermia is the only approved medical treatment 
to minimize brain injury in infants with HIE.  Research has shown that therapeutic 
hypothermia is beneficial in term and late preterm neonates with HIE. To be effective HIE 
must be applied within six hours of the baby’s birth.1 However, therapeutic hypothermia only 
provides beneficial outcomes in less than 50% of the treated patients.
1-3
 Therefore, effective 
pharmacological therapeutic agents able to be used as an adjunct to hypothermia are needed 
to improve neonatal outcome.  
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Preclinical studies have shown that melatonin improves hypothermia efficacy.
4-6
  
Melatonin is a naturally occurring substance mainly produced from the pineal gland and well 
known for its role in regulating the circadian rhythm. However, Melatonin also possesses 
pleiotropic effects including free radical scavenger activity and stimulation of anti-oxidant 
enzymes. In addition, melatonin exhibits immunomodulatory effects in the presence of an 
exacerbated immune response.
7-9
  Due to these pleiotropic and immunomodulatory effects, 
melatonin can reduce several key components involved in the development of hypoxic-
ischemic injury. Studies in preclinical models of perinatal HIE have demonstrated that 
melatonin minimizes cell death and improves outcomes.
10-14
 Human studies have also 
provided evidence of efficacy.  In asphyxiated neonates, melatonin administered at the dose 
of 10 mg PO every 2 hours for 8 doses reduced malondialdehyde and nitrate/nitrite 
concentrations without side effects when compared to the infants given placebo. This 
reduction in malondialdehyde and nitrate/nitrite concentrations indicate that lipid 
peroxidation and oxidative damage were reduced.
15
 A recent study examined the effect of 
five daily enteral doses of melatonin on clinical, biochemical, neurophysiological, and 
radiological outcomes of neonates with HIE. Melatonin-treated neonates in this study had 
decreased brain injury compared to controls.
16
  
 
The evidence from preclinical studies indicates that melatonin is a remarkable 
neuroprotective therapy, and melatonin’s use may help avoid the sequelae of HIE in 
neonates.
17
 However, the safety, pharmacokinetics (PK), dosing, and effectiveness of 
melatonin in infants with HIE undergoing hypothermia is still unclear.  Thus, trials aimed at 
assessing safety and PK must occur prior to large randomized controlled trials. To protect the 
vulnerable neonatal population, all information collected during a drug trial must be carefully 
evaluated. In addition, PK data must be evaluated to find an appropriate dosing schedule. The 
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PK data collected during these studies will provide the first step in describing the 
dose‐ concentration and dose‐ toxicity response relationships, which is essential in designing 
a future clinical trial protocol. 
 
Here we report the first results of a clinical study approved by the FDA 
(ClinicalTrials.gov Identifier: NCT02621944). The aim of this study was to establish the 
safety and PK of melatonin after enteral administration to neonates with HIE undergoing 
hypothermia.  In this study we used a novel manufactured preparation of melatonin (Int. Pat. 
Appl. PTC/IB2016/051235) that did not contain excipients like alcohol or other substances 
used to increase melatonin solubility.  The absence of excipients helped reduce the possibility 
of side effects from exogenous substances.  
 
2|  Materials and Methods  
2.1 | Study population 
The study was designed and conducted in accordance with the Declaration of Helsinki 
and approved by The University of Florida Institutional Review Board (ClinicalTrials.gov 
Identifier: NCT02621944).  Prior to enrolment in the study, written informed consent was 
obtained from the parents of five neonates admitted to the Neonatal Intensive Care Unit at the 
University of Florida, Gainesville, USA.  Subjects were enrolled in the study within 24 hours 
of birth. Patients with HIE eligible for hypothermia therapy were recruited. Entry criteria for 
hypothermia included a gestational age of 36 weeks or greater, a birth weight of 1.8 kg or 
greater, and less than or equal to 6 hours of age. The neonates had evidence of moderate or 
severe encephalopathy as defined by seizures or abnormalities on a modified Sarnat exam 
(level of consciousness, spontaneous activity, posture, tone, primitive reflexes including suck 
and Moro, and autonomic system findings including pupils, heart rate, and respirations).  
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Evidence of hypoxic-ischemic injury was defined as 1) a pH of 7.0 or less and/or a base 
deficit of greater than 16, or 2) a pH between 7.01-7.15 and/or a base deficit between 10-
15.9, or 3) no blood gas available and an acute perinatal event (cord prolapse, fetal 
bradycardia, uterine rupture).
18
 Neonates with suspected inborn errors of metabolism 
(elevated ammonia) and hypoglycemia, clinical signs and symptoms consistent with 
meningitis detected upon sepsis evaluation, or a diagnosis of congenital abdominal surgical 
problems along with multiple congenital anomalies and/or chromosomal abnormalities were 
excluded.  
 
2.2 | Dose and medication 
A stable and sterile aqueous melatonin solution (0.4 mg/ml) free from excipients (Int. 
Pat. Appl. PTC/IB2016/051235) was prepared by Industria Farmaceutica Galenica Senese 
S.R.L. (Monteroni d'Arbia, Siena, IT). Neonates enrolled in the study received the first dose 
of melatonin within 24 hours of life with a target of 12 hours of life or less.  The drug was 
infused via enteral route through an OG tube at a dose of 0.5 mg/kg. The infusion started 1 
hour after the neonates reached the target temperature of 33.5°C (hypothermia).    Prior to 
administration, the investigational drug pharmacy at the University of Florida diluted the 
melatonin with normal saline to a final concentration of 6 ml. A feeding pump infused the 
solution over 4 hours at a rate of 1.5 ml/h. The standardized volume, infusion time, and dose 
allowed for comparisons of the pharmacokinetics between subjects.   
 
Blood samples (1 ml) were collected from an indwelling arterial catheter immediately 
before (time 0) and 1, 3, 6, 12, 24, 48, and 96 hours after starting the melatonin infusion. 
Blood samples were collected in blood collection tubes containing lithium heparin (cat 
#367884, BD Vacutainer
®
, Franklin Lakes, NJ) and stored at 4°C until centrifugation. The 
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sample was centrifuged for 10 minutes at 2000g at 4°C. The plasma (500 µL) was transferred 
to a 2.0 ml red cap self-standing microcentrifuge tube (cat # 1420-9704, USA Scientific, 
Ocala, FL) and immediately stored at - 80°C. 
 
2.3 | Melatonin tolerance 
During the entire period of melatonin administration, the neonate was monitored 
using vital monitoring (heart rate, respirations, blood pressure), systemic and cerebral 
saturations, and abdominal exams. Specifically, the Vital Sync™ (Medtronic, formerly 
Covidien, Minneapolis, MN) monitoring platform captured vital sign data. Every 30 seconds, 
the Vital Sync™ captured the cerebral saturation plus the heart rate, arterial blood pressure, 
cuff blood pressure, and pulse oximeter saturation of each patient. INVOS™ 
Cerebral/Somatic Oximetry (Medtronic, formerly Covidien, Minneapolis, MN) captured 
cerebral saturations.  Infant-Neonatal Sensors with near-infrared spectroscopy measured 
regional mixed venous-arterial saturations. Sensors were placed over either the left or right 
side of the forehead. Data were captured prior to, during, and after melatonin infusion. The 
data were exported from the Vital Sync
TM
 as a spreadsheet and prepared for analysis.  
Abdominal exams that included abdominal circumference were performed prior to and hourly 
during the four-hour infusion. 
 
2.4 | Melatonin concentration assay 
Plasma melatonin concentrations were measured by high-performance liquid 
chromatography (HPLC) and mass spectrometry (MS/MS) (Agilent Technologies 1200 series 
system and an ABSciex API 4000 triple-quadrupole mass spectrometer) according to the 
method of Wang et al.,
19
 as previously described.
20
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2.5 | Pharmacokinetic modeling and analysis 
Individual patient data and population data were analyzed by adapting the classical 
one-compartment model for intravenous (IV) infusion to nasogastric infusion.  The classical 
one-compartment model for IV infusion is based on a constant rate of infusion. The model 
divides the function of concentration (C) vs time (t) into two different intervals:  
 
           
                          
                                          
  
 
where      is the time of IV infusion, A is a constant, and     is the elimination constant. In 
the case of nasogastric infusion, however, the model leads to an incorrect fitting due to the 
time-delay caused by absorption through the gastric mucosa. To overcome this problem, a 
term was introduced that took into account this delay. This term, defined as tabs , considers 
that the absorption rate is constant. The new equation is thus:  
 
2)         
                               
                                                    
  
 
Because tabs is not directly measurable, we estimated tabs by optimizing its value through 
maximization of   . Using the PK Solver© 2.0 software,21 we computed    for virtual values 
of      ranging from 4 to 10 h with steps of 0.1 h in order.  This procedure enabled us to 
detect the tinf value that maximized   . The best estimates of      were found through the 
difference obtained between the virtual value of      and its real value, i.e.      = 4 h. For the 
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measured data set, we obtained an estimated tabs of 2.8 h with a virtual value of           . 
These values corresponded to         , indicating an excellent goodness of fit.  
The peak concentration time (    ) and the maximal concentration (    ) were then 
calculated as follows:  
 
3)                  
4)                                  
 
2.6 | Simulation of plasma concentration time profiles following repeated melatonin 
infusions. 
We used the real data obtained in the neonatal PK study to estimate in silico the PK 
profile of repeated melatonin infusions.  The simulation was based on the hypothesis that 
after each administration, melatonin followed the same PK of the first infusion. For a generic 
k
-th
 infusion, the model can be described as: 
 
                 
 
   
 
where time (t) is in hours. Using this model, we simulated the administration of seven 
infusions repeated every 24 h.  
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3 | RESULTS 
3.1 | Demographics  
 The average gestational age of the enrolled subjects was 39.8±0.75 weeks with an 
average birthweight of 3.46±0.05 kg. Of the five subjects, four were male, and one was 
female. The remainder of the demographics are summarized in Table 1. Below is a short 
description of the clinical course of each subject.   
 
3.2 | Clinical Data and Tolerance to melatonin   
 Patient M001 was outborn at an estimated gestational age (EGA) of 39 weeks. 
Delivery occurred by C-Section due to non-reassuring fetal heart tones during labor. At 
delivery, a placental abruption was noted. Apgar scores were 1/1/1/3 at 1’, 5’, 10’, and 15’, 
respectively. The patient required cardiopulmonary resuscitation (CPR) for 3 minutes and 
was intubated at 5 minutes of life. The cord blood gas demonstrated pH 6.895, PaCO2 73 mm 
Hg, PaO2 <16 mm Hg, HCO3 14 mEq/L, and a base excess (BE) -19 with a lactic acid of 
16.6mmol/L. The initial Sarnat score was stage II. The neonate was intubated for 2 days, 
including during the melatonin infusion. The melatonin infusion was started at 8 hours of life. 
The HR gradually decreased from a mean of 117±7 bpm prior to infusion to 109±7 bpm 
during the infusion and 95±7 bpm for 12 hours after the infusion (Figure 1A, panel a).  
Cerebral and systemic saturations and the MAP remained constant prior to, during, and after 
the infusion (Figure 1A, panels b-d). The baseline abdominal circumference was 31 cm and 
increased to 32 cm by the completion of the infusion (Figure 2).  The initial abdominal exam 
revealed a full but soft abdomen that was not tender to palpation with active bowel sounds.  
The final exam revealed a full but soft abdomen that was not tender to palpation. An MRI 
obtained at day of life (DOL) 4 did not have evidence of hypoxic-ischemic injury. Small foci 
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of hemorrhage were present in both cerebellar hemispheres. The MRI also showed a small-
volume subdural hematoma posteriorly on the right. The subject was discharged on DOL 11. 
Patient M002 was inborn at the EGA of 41 weeks. Delivery occurred via emergent C-
section due to non-reassuring fetal heart tones. Apgar scores were 1/2/3 at 1’, 5’, and 10’, 
respectively. The arterial cord gas results were as follows:  pH 7.24, PaCO2 61 mmHg, PaO2 
14.3 mmHg, HCO3 14 mEq/l, and BE -3.8. The neonate’s initial arterial gas results were pH 
7.21, PaCO2 33 mmHg, PaO2 147 mmHg, and BE -15. The neonate’s initial Sarnat score was 
stage III. The patient was intubated for 4 hours and then extubated to room air. The neonate 
was on room air during the melatonin infusion. The infusion was started at 14 hours of life.   
The HR mean was 84±19 bpm prior to infusion, 70±10 bpm during the infusion, and 107±17 
bpm after the infusion (Figure 1B, panel e).  The MAP was 76±3 mmHg prior to infusion, 
73±6 mmHg during the infusion, and 68±5 mmHg after the infusion (Figure 1B, panel f).  
The systemic and cerebral saturations were unchanged prior to, during, and after the infusion 
(Figure 1B, panels g-h).  The abdominal circumference was 31.5 cm prior to the infusion and 
decreased to 31.0 cm by the completion of the infusion (Figure 2).  The abdominal exam at 
baseline revealed a non-tender, non-distended abdomen with active bowel sounds.  The exam 
was unchanged at the completion of the infusion.  The MRI obtained after the completion of 
hypothermia on DOL 3 did not reveal any hypoxic-ischemic injury. The patient was 
discharged on DOL 7.   
 Patient M003 was inborn at the EGA of 40 weeks. The delivery was complicated by a 
prolonged rupture of membranes, chorioamnionitis, shoulder dystocia, and a nuchal cord. 
After delivery, the patient did not have any respiratory effort and had a heart rate less than 60 
bpm, poor tone, and poor color. The patient’s airway was suctioned with a catheter. Then, the 
patient was placed on positive pressure ventilation with 100% oxygen.  The heart rate 
improved with positive pressure ventilation. Apgar scores were 1/6 at 1’ and 5’, respectively. 
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The arterial cord gas results were as follows: pH 7.06, PaCO2 79 mmHg,  PaO2 23 mmHg, 
HCO3 21 mEq/l, and BE -12.3.  The arterial blood gas results on admission were as follows: 
pH 7.38, PaCO2 19 mmHg, PaO2 99 mmHg, HCO3 18 mEq/l, and BE -7.0. The initial Sarnat 
score was stage II. The patient was placed on continuous positive airway pressure for 24 
hours. The melatonin infusion was started at 6 hours of life and occurred during the time of 
continuous positive airway pressure. The HR mean was 108±13 bpm prior to infusion, 84±13 
bpm during the infusion, and 90±20 bpm after the infusion (Figure 1C, panel i).  The mean 
cerebral oximetry was 81±2% prior to infusion, 68±8% during the infusion, and 75±3% after 
the infusion (Figure 1C, panel n).  The systemic saturations and MAP were unchanged prior 
to, during, and after the infusion (Figure 1C, panels l and m).  The abdominal circumference 
was 34.5 cm prior to the infusion and remained unchanged at the completion of the infusion.  
The abdominal exam at baseline revealed a non-tender, non-distended abdomen with active 
bowel sounds.  The abdominal exam was unchanged at the completion of the infusion (Figure 
2).  The MRI at DOL 5 demonstrated no evidence of hypoxic-ischemic injury.  The subject 
was discharged on DOL 7.  
 Patient M004 was outborn at the EGA of 40 weeks.  Delivery occurred via 
spontaneous vaginal delivery, and the neonate was limp and apneic at delivery. The health 
care team found the neonate difficult to resuscitate via bag valve mask, so the neonate was 
intubated. The neonate continued to require high respiratory pressure support. The heart rate 
diminished, and CPR was initiated. In addition, the patient received several rounds of 
epinephrine for a low heart rate. The subject had bilateral tension pneumothoraces. Bilateral 
chest tubes were placed, and the heart rate improved. The initial cord blood gas was as 
follows: pH 6.99, PaCO2 25 mmHg, PaO2 98 mmHg, HCO3 23 mEq/l, and BE -9.0. The 
initial Sarnat score was stage II. The patient was given one dose of surfactant and required 
high frequency oscillator ventilation and inhaled nitric oxide due to persistent pulmonary 
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hypertension of the newborn (PPHN) and meconium aspiration syndrome (MAS). The 
melatonin infusion was started at 9 hours of life.   The cerebral oximetry mean was 71±9% 
prior to infusion, 77±7% during the infusion, and 85±7% after the infusion (Figure 1D, panel 
r). The neonate’s heart rate, systemic saturations, and MAP were unchanged prior to, during, 
and after the infusion (Figure 1D, panels o-q).  The abdominal circumference was 32 cm 
prior to the infusion and was unchanged at the completion of the infusion (Figure 2).  The 
abdominal exam at baseline revealed a full but soft abdomen without active bowel sounds.  
The exam was unchanged at the completion of the infusion.  The MRI obtained on DOL 8 
demonstrated a subdural haemorrhage and a 1.2 cm parenchymal hemorrhage in the left 
occipital lobe, but no evidence of hypoxic-ischemic injury. The subject was discharged on 
DOL 21. 
 Patient M005 was outborn at an EGA of 39 weeks. Delivery occurred via emergent C-
section due to non-reassuring fetal heart tones. Meconium stained fluid was noted at delivery. 
The neonate’s Apgars were 1/5/7 at 1’, 5’, and 10’, respectively, and the subject required 
intubation at delivery. An initial venous blood gas upon arrival to the NICU was as follows: 
pH 7.03, PaCO2 56 mmHg, PaO2 68 mmHg, HCO3 15 mEq/l, BE -17. The neonate’s initial 
Sarnat score was stage II. The neonate required high frequency oscillator ventilation and 
inhaled nitric oxide and was evaluated for possible extracorporeal membrane oxygenation 
(ECMO). The melatonin infusion was started at 9 hours of life.   The heart rate, systemic 
saturations, MAP, and cerebral saturations were unchanged prior to, during, and after the 
infusion (Figure 1E).  The abdominal circumference was 31 cm prior to the infusion and 31.5 
cm at the completion of the infusion (Figure 2).  The abdominal exam at baseline revealed a 
non-tender, non-distended abdomen without active bowel sounds.  The exam done at the 
completion of the infusion revealed a soft abdomen with active bowel sounds.  An MRI on 
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DOL 9 revealed a small punctate focus of T1 signal in the right periventricular white matter. 
The subject was discharged at DOL 30.      
 
3.3 | Melatonin pharmacokinetics  
We applied the modified one-compartment model for intravenous infusion to the 
plasma concentrations of melatonin detected after 0.5 mg/kg intragastric infusion. The dose, 
calculated for the body weight of each neonate, was administered over 4 hours. The data of 
the individual patients and the population were analyzed at the selected times before and after 
the end of the infusion.   
The measured concentrations of melatonin in plasma are reported in Table 2. Of the 5 
neonates studied, 4 showed median basal serum melatonin concentrations of 20.6 pg/mL. A 
baseline melatonin concentration was not detected in patient M003. The highest plasma 
melatonin concentrations were obtained between 3 and 12 h after the end of the infusion 
(time points 7 and 16 h, respectively). The measured peak concentration varied greatly 
among patients (0.08-0.28 g/mL). 
Table 3 reports the estimated PK parameters in individual patients as mean±SE.  As 
shown, the individual mean maximal serum concentration (Cmax) was 0.27±0.04 μg/mL (0.25 
g/mL in the population analysis), whereas the individual mean time to maximal 
concentration (Tmax) was 8.66±1.12 h (6.8 h in the population analysis). Using the modified 
one compartment model analysis, the individual patients had a an elimination half-life (T1/2 ) 
of 50.90±36.43 h (26.43 h in the population analysis), a volume of distribution (V) of 
5.67±0.08 L, and a clearance (CL) of 0.21±0.07 L/h. The V and CL data obtained in the 
population analysis (V=6.25 L; CL=0.16 L/h) were weight-corrected (V=1.80 L/kg and 
CL=0.046 L/h/kg).  In the individual analysis, the AUC calculated for the entire study period 
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was 17.44±9.92 μg/mL*h, whereas in 24 h the AUC was 4.35 μg/mL*h. The high variability 
obtained in most parameters was mainly due to the high values of patient M001.  
The fitting of the data obtained with the model described in the methods section and 
the relative estimates of the pharmacokinetic parameters are reported in Figure 3. These 
estimates are in agreement with the mean values calculated for the individual patients (Table 
3). 
 
3.4 | Simulation of melatonin pharmacokinetics following repeated melatonin infusions 
We used the in vivo data obtained in the PK study in neonates to estimate in silico the 
PK profile of repeated melatonin infusions. This approach allowed us to assess the number of 
infusions required to reach the steady-state and the AUC values. The simulation was based on 
the hypothesis that melatonin followed the same PK of the first infusion for each subsequent 
administration. Figure 4 shows that the steady-state can be reached after 4 infusions repeated 
every 24 h. According to the model, the lowest and highest concentrations that can be 
reached with this dosage are 0.31 μg/mL and 0.48 μg/mL, respectively. The expected AUC at 
the steady-state after the 4
th
 virtual infusion is 9.71 μg/mL*hr.  
 
4  | DISCUSSION 
When preclinical studies of a new medication are extrapolated to clinical studies, a 
dose that is effective and safe must be determined. This extrapolation is particularly difficult 
in neonatal studies because varied maturation rates and developmental ages can vary dose 
responses. Because the PK and safety profile of a new medication is unknown, a dose 
escalation study is the first investigative step.  In a dose escalation study, a low dose is 
administered first to a group of patients. If safety issues do not arise, a new group of patients 
receives a higher dose.
22
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The results reported here are the first data obtained in an FDA-approved clinical study 
that use the dose-escalation approach to identify a safe and potentially effective dose of 
melatonin for neonates with HIE undergoing hypothermia.  In preclinical experiments the 
most effective melatonin dose was 10-15 mg/kg,
4,11,23
 although efficacy was also 
demonstrated at lower doses.
11,14
 When preclinical studies are translated into clinical 
experimentation, researchers must consider allometry when extrapolating the dosing.
24
 
 Generally, in clinical studies performed in adult subjects, a linear correlation between dose 
and body surface area is assumed. Dose extrapolation is more complex in neonates because 
the drug PK may be different due to varied rates of maturation and development of the 
different organs.
22,24,25
  
Based on previous studies of the safety of melatonin administration,
15,16
 we started a 
dose escalation study to assess the safety and PK in neonates undergoing hypothermia 
(ClinicalTrials.gov Identifier: NCT02621944).  We started with a melatonin dose of 0.5 
mg/kg.  This dose was chosen based on our previous study of melatonin administration in 
preterm neonates.
20
 This previous study showed a higher half-life of melatonin in neonates as 
compared to animals and adults. Notably, Merchant et al. (2013) found similar results.
26
 To 
our knowledge we are the first group to carry out a structured study that assesses the safety 
and PK profile of enterally-administered melatonin in neonates with a diagnosis of HIE and 
undergoing hypothermia.  
 
4.1 | Melatonin tolerance 
 We administered 0.5 mg/kg melatonin enterally to neonates with HIE undergoing 
therapeutic hypothermia.  The melatonin was well tolerated and did not result in any 
abdominal complications.  Neither emesis nor abdominal distension occurred during or after 
the infusion.  Serial abdominal exams during and after the infusion did not reveal any 
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changes.  In addition, none of the neonates experienced increased somnolence or sedation 
during or after the melatonin infusion.  The patients’ vital signs did not exhibit major clinical 
changes during or after the infusion. The heart rates of patients M001, M002, and M003 
decreased over time, which is consistent with neonates undergoing hypothermia who did not 
receive melatonin. The neonates in our study were treated based on an established 
hypothermia protocol that uses routine sedation with fentanyl.  One known effect of fentanyl 
is a decreased heart rate.  Patient M002’s low heart rate during the infusion was most likely 
due to over sedation with fentanyl. This patient’s heart rate was already decreasing to the 70-
80 range in the hour prior to infusion.  When the sedation was decreased during the infusion, 
the heart rate of patient M002 rose.        
 
4.2 | Melatonin pharmacokinetics and dose extrapolation 
We found that four of the five enrolled neonates showed low but detectable basal 
melatonin values (median value 20.6 pg/mL). These low basal melatonin values were similar 
to the values in our previous study of preterm neonates.
20
 In this study, we enterally infused a 
new proprietary melatonin preparation that did not contain excipients. A preparation without 
excipients reduces the possibility of toxic effects by unwanted substances.  
Our results show that the melatonin preparation was well absorbed enterally by 
neonates undergoing hypothermia. After infusion with 0.5 mg/kg melatonin, the Cmax reached 
0.25 g/ml. In an earlier study the same dose was administered as a single bolus to preterm 
neonates, who subsequently experienced a higher Cmax value (0.44 g/ml).
20
 The Tmax 
estimated in the population analysis was 6.80 h, and the individual patient Tmax mean was 
8.66 h, range 6.5-13 h. The Tmax varied widely among patients.  
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In our population study in which melatonin was infused over time, the AUC was 4.35 
g/mL*h at 24 h. This AUC was lower compared to the AUC of 10.48 g/mL*h found in a 
previous study that administered the same dose of melatonin as a single bolus..
20
 The 
melatonin half-life and CL were prolonged, and V was decreased compared to adult
27
 and 
animal models.
28
  This finding is consistent with previous data obtained in preterm 
neonates.
20,26
 The inter-individual variations in the PK parameters in our study could be 
caused by differences in absorption, distribution, metabolism, or excretion, but the exact 
causes and clinical implications remain unestablished. Studies aimed at addressing these 
variability issue are in progress. 
The in silico study simulated 7 infusions of melatonin repeated every 24 h. The 
simulation indicated that after each infusion, melatonin would follow the same PK of the first 
infusion. Using this approach, we estimated that the steady state would be reached after four 
infusions. This in silico analysis also showed that at the steady state the Cmax and AUC values 
would be similar to those previously obtained after bolus administration (estimate after 
infusion: Cmax 0.48 μg/mL, AUC 9.71 μg/mL*h; bolus administration: Cmax 0.44 μg/mL, 
AUC 10.48 μg/mL*h).20  Overall, these data, compared with our previous study in preterm 
neonates, indicate that hypothermia does not affect the PK of melatonin. In addition, high 
blood concentrations of melatonin in humans are achievable with lower doses compared to 
animal dosing.  
  Recently, we assessed the protective effect of melatonin in organotypic slice cultures 
of the hippocampus. Organotypic slice cultures maintain several aspects of structural and 
synaptic organization of the original tissue. In addition, the maturation of varied cell types 
and cooperation between neurons and glial cells are similar in organotypic slice cultures and 
the original tissue.  Because organotypic slice cultures behave in similar ways to the original 
tissue, we were able to investigate the effects of melatonin on the hippocampus in vitro and 
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extrapolate the results to the in vivo situation.
5
 Using this system, we found a synergy 
between melatonin and hypothermia with melatonin concentrations of 25 µM and 50 µM and 
6 hours of hypothermia. In the present study, we found that after a single infusion of 0.5 
mg/kg melatonin, the AUC was 4.35 µg/mL*h, equivalent to 18.73 µM. If we assume that 
our in silico simulation is correct, at the steady state the AUC should be 9.71 µg/mL*h, 
equivalent to 41.51 µM. This steady state concentration is in line with the effective 
concentration found in our in vitro experiments.
5
  
In our previous work we found a direct correlation between the dose of melatonin and 
the AUC.
20
 The calculated AUC ratio of infusion/bolus of 0.5 mg/kg melatonin is 0.41 (4.35 
µg/mL*h vs 10.48 µg/mL*h, respectively). Thus, after an enteral infusion of 5 mg/kg 
melatonin, the estimated AUC could reach about 48 µg/mL*h, equivalent to 207 µM. If 
melatonin is given intravenously ,as in the case of  Merchant et al.(2013),
26
 a 0.5 mg/kg dose 
should also result in higher AUC values and faster steady-state than an enterally administered 
dose.  If we assume that these extrapolations are correct, then the concentration obtained with 
these low doses should be even higher than the doses that showed synergy with hypothermia 
in studies with hippocampal slices.
5
  Currently we are treating patients with melatonin doses 
up to 5 mg/kg to assess safety and confirm our PK estimates.        
 
4.3 | Conclusions 
In the present study we administered melatonin by enteral infusion because it was the 
safest route for a study in neonates.  The preparation is also suitable for intravenous infusion. 
The dose administered was the lowest dose proposed in the study approved by the FDA. The 
results of this study give important indications for future clinical studies aimed at assessing 
melatonin efficacy in HIE. The dose of melatonin, depending on the route of administration, 
should not exceed 1-5 mg/kg. This dosing range results in AUC values higher than effective 
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AUC values in hippocampal slices treated with hypothermia. At these doses, melatonin can 
be administered without the presence of excipients in the preparation, reducing the risk of 
side effects by unwanted substances. In addition, IV administration is preferred because 
bioavailability is 100%. IV administration of melatonin bypasses absorption through the 
gastric mucosa, so blood concentrations vary less among patients, and an effective blood 
concentration is achieved faster. We trust that our results will lay the foundation for larger 
randomized studies aimed at evaluating the efficacy of melatonin in association with 
hypothermia or when hypothermia cannot be applied. 
Currently the length of melatonin treatment in HIE for optimal neuroprotection is 
unknown. Preclinical studies are necessary because new evidence shows that melatonin can 
enhance cell and tissue regeneration and is protective during acute neurodegeneration.
29,30
 
The injured immature brain holds high-level neural plasticity and could be particularly 
susceptible to treatment modalities such as melatonin that can trigger neuron generation 
(reactive neurogenesis) and creation of new neural networks.   
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LEGEND TO FIGURES 
Figure 1 
The heart rate, mean arterial blood pressure (MAP), Systemic Saturations and Cerebral 
Saturations for subject M001 (Figure 1A, panels a-d), M002 (Figure 1B, panels e-h), M003 
(Figure 1C, panels i-n), M004 (Figure 1D, panels o-r), M005 (Figure 1E, panels s-v).   The 
parameters are shown prior to infusion (PI), during the infusion (DI) and after the infusion 
(AI) of melatonin (mean±SEM).        
Figure 2 
The abdominal circumference (cm) for subjects M001-M005 are graphed over time (hours).  
Time point 0 was prior to the infusion and represented a baseline measurement.   
Figure 3 
Population analysis of plasma melatonin concentrations after enteral infusion of 0.5 mg/kg 
melatonin in neonates subjected to hypothermia. A) Measured (symbols) and predicted (line) 
melatonin concentrations. B) Pharmacokinetic parameter estimates in the population analysis. 
The mathematical model used for this analysis is reported in the Methods section.  
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Figure 4 
In silico pharmacokinetic profile of melatonin infusions repeated each 24 h. The simulation 
was based on the hypothesis that after each administration melatonin followed the same 
pharmacokinetic profile of the first infusion. The mathematical model used for this analysis is 
reported in the Methods section. 
 
Table 1: Demographic and clinical data of patients with HIE enrolled 
 
Patient M001 M002 M003 M004 M005 Mean ± SE 
GA (wks) 39 41 40 40 39 39.8±0.75 
Sex (M:F) M M M F M  
BW  (Kg) 3.46 3.54 3.57 3.46 3.26 3.46±0.05 
Apgar 1’ 1 1 1 1 1 1 
Apgar 5’ 1 2 6 5 5 3.8±1.94 
Apgar 10’ 1 3 6 N/A 7 4.25±2.39 
Initial pH 6.89 7.21 7.06 6.99 7.03 7.04±0.10 
BD -19 -15 -12 -9 -17 -14.4±3.56 
SS II III II II II  
Seizures No  No  No No 
Yes  
(clinical
) 
 
ECS Yes Yes  No  No  Yes   
Intubation in DR Yes Yes No Yes  Yes   
Outborn/Inborn 
Outbor
n 
Inbor
n 
Inbor
n  
Outbor
n  
Outborn   
Vasopressors No  No  No  No  Yes   
Hour of life hypothermia  
initiated 
4 0 3 3.5 5 3.1±1.69 
Hour of life melatonin 
administered 
8 14 6 9 9 9.2±2.64 
GA = Gestational Age, BW = Birth Weight, BD = Initial Base Deficit, SS = Initial Sarnat 
Score, ECS = Emergency C-section, DR = Delivery Room. 
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Table 2: Melatonin plasma concentrations at different time after  
0.5 mg/kg 4h-infusion  
 
 
 
 
 
 
 
 
 
 
 
Table 3. Estimates of melatonin pharmacokinetic parameters in patients with HIE 
enrolled 
Patient  M001 M002 M003 M004 M005 Mean ± SE 
Kel 0.003 0.063 0.038 0.079 0.033 0.043 ± 0.012 
T1/2 (h) 196.33 10.97 17.83 8.74 20.57 50.90 ± 36.43 
AUC (µg/mL/h) 56.92 8.76 8.68 3.64 9.20 17.44 ± 9.92 
Tmax(h) 7.8 7.9 13 6.5 8.1 8.66 ± 1.12 
Cmax(µg/mL) 0.19 0.43 0.26 0.22 0.27 0.27 ± 0.04 
V(L/kg) 8.62 3.19 5.29 5.99 5.25 5.67±0.08 
CL (L/h) 0.03 0.20 0.20 0.47 0.17 0.21±0.07 
 
Kel, elimination constant; T1/2, elimination half-time; AUC, Area Under concentration-
time Curve; Tmax, time to reach maximal serum concentration; Cmax, maximal serum 
concentration; V, apparent Volume of distribution; CL, Clearance. 
Melatonin 0.5 mg/kg 
4h-infusion 
Time (h) 
Median 
(range) ( g/mL) 
0 
20.6*10
-6
  
(8.7*10
-6
-33.1*10
-6
) 
5 
0.16 
(0.13-0.34) 
7 
0.20 
(0.10-0.36) 
10 
0.20 
(0.17-0.37) 
16 
0.24 
(0.08-0.28) 
28 
0.12 
(0.04-0.23) 
52 
0.04 
(0.005-0.22) 
100 
0.008 
(0.001-0.10) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
